![Efficacy and safety of lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in breast cancer patients in Poland Efficacy and safety of lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in breast cancer patients in Poland](https://www.archivesofmedicalscience.com/f/pictures/140623_bf70d.jpg)
Efficacy and safety of lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in breast cancer patients in Poland
![PDF) Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy PDF) Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy](https://i1.rgstatic.net/publication/304378260_Immunogenicity_Assessment_of_Lipegfilgrastim_in_Patients_with_Breast_Cancer_Receiving_Chemotherapy/links/57cc177408ae3ac722b45efe/largepreview.png)
PDF) Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy
LONQUEX Trademark of TEVA Pharmaceutical Industries Ltd. Serial Number: 85427862 :: Trademarkia Trademarks
![Lonquex - Lipegfilgrastim 10mg/ml - 1 Seringa Segurança Preenchida 0,6ml SC (2 A 8C) - Teva - ÁgilMed - Medicamentos Especiais e Nutrição Clínica Lonquex - Lipegfilgrastim 10mg/ml - 1 Seringa Segurança Preenchida 0,6ml SC (2 A 8C) - Teva - ÁgilMed - Medicamentos Especiais e Nutrição Clínica](https://cdn.awsli.com.br/300x300/476/476175/produto/33796109/adb4eb413d.jpg)
Lonquex - Lipegfilgrastim 10mg/ml - 1 Seringa Segurança Preenchida 0,6ml SC (2 A 8C) - Teva - ÁgilMed - Medicamentos Especiais e Nutrição Clínica
![Immunogenicity assessment of PEGylated proteins, Lonquex, a PEGylated G-CSF case study - ScienceDirect Immunogenicity assessment of PEGylated proteins, Lonquex, a PEGylated G-CSF case study - ScienceDirect](https://ars.els-cdn.com/content/image/3-s2.0-B9780444640819000061-f06-02-9780444640819.jpg)
Immunogenicity assessment of PEGylated proteins, Lonquex, a PEGylated G-CSF case study - ScienceDirect
![LONG-ACTING G-CSF (LIPEGFILGRASTIM, “LONQUEX”) FOR STEM CELL.... EHA Library. Danylesko I. Jun 15 2019; 267164 LONG-ACTING G-CSF (LIPEGFILGRASTIM, “LONQUEX”) FOR STEM CELL.... EHA Library. Danylesko I. Jun 15 2019; 267164](https://library.ehaweb.org/image/abstract/eha_2019/EHA-1516/ImagePictures_6885492.png)
LONG-ACTING G-CSF (LIPEGFILGRASTIM, “LONQUEX”) FOR STEM CELL.... EHA Library. Danylesko I. Jun 15 2019; 267164
![G-CSF (Granulocyte Colony Stimulating Factors) Market Analysis, Size And Trends Global Forecast To 2022-2030 G-CSF (Granulocyte Colony Stimulating Factors) Market Analysis, Size And Trends Global Forecast To 2022-2030](https://www.thebusinessresearchcompany.com/infographimages/210104_G-CSF_(Granulocyte%20Colony%20Stimulating%20Factors).png)
G-CSF (Granulocyte Colony Stimulating Factors) Market Analysis, Size And Trends Global Forecast To 2022-2030
![Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profile - Abdolzade‐Bavil - 2016 - The Journal of Clinical Pharmacology - Wiley Online Library Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profile - Abdolzade‐Bavil - 2016 - The Journal of Clinical Pharmacology - Wiley Online Library](https://accp1.onlinelibrary.wiley.com/cms/asset/cd8a4c53-d3fb-452f-8bc2-d8f511f0a210/jcph578-fig-0002-m.jpg)